Gorris Myrte, van Huijgevoort Nadine C M, Farina Arantza, Brosens Lodewijk A A, van Santvoort Hjalmar C, Groot Koerkamp Bas, Bruno Marco J, Besselink Marc G, van Hooft Jeanin E
Amsterdam UMC, Location University of Amsterdam, Department of Gastroenterology and Hepatology, 1081 HV Amsterdam, The Netherlands.
Amsterdam Gastroenterology Endocrinology Metabolism, 1105 BK Amsterdam, The Netherlands.
Cancers (Basel). 2022 Aug 30;14(17):4228. doi: 10.3390/cancers14174228.
Background: Outcome after resection of pancreatic ductal adenocarcinoma associated with pancreatic cystic neoplasms (PCN-PDAC) might differ from PDAC not associated with PCN. This nationwide, registry-based study aimed to compare the overall survival (OS) in these patients. Methods: Data from consecutive patients after pancreatic resection for PDAC between 2013 and 2018 were matched with the corresponding pathology reports. Primary outcome was OS for PCN-PDAC and PDAC including 1-year and 5-year OS. Cox regression analysis was used to correct for prognostic factors (e.g., pT-stage, pN-stage, and vascular invasion). Results: In total, 1994 patients underwent resection for PDAC including 233 (12%) with PCN-PDAC. Median estimated OS was better in patients with PCN-PDAC (34.5 months [95%CI 25.6 to 43.5]) as compared to PDAC not associated with PCN (18.2 months [95%CI 17.3 to 19.2]; hazard ratio 0.53 [95%CI 0.44−0.63]; p < 0.001). The difference in OS remained after correction for prognostic factors (adjusted hazard ratio 1.58 [95%CI 1.32−1.90]; p < 0.001). Conclusions: This nationwide registry-based study showed that 12% of resected PDAC were PCN-associated. Patients with PCN-PDAC had better OS as compared to PDAC not associated with PCN.
与胰腺囊性肿瘤相关的胰腺导管腺癌(PCN-PDAC)切除术后的结果可能与不伴有PCN的PDAC不同。这项基于全国登记系统的研究旨在比较这些患者的总生存期(OS)。方法:将2013年至2018年间因PDAC接受胰腺切除的连续患者的数据与相应的病理报告进行匹配。主要结局是PCN-PDAC和PDAC的OS,包括1年和5年OS。采用Cox回归分析校正预后因素(如pT分期、pN分期和血管侵犯)。结果:共有1994例患者接受了PDAC切除术,其中233例(12%)为PCN-PDAC。与不伴有PCN的PDAC相比,PCN-PDAC患者的中位估计OS更好(34.5个月[95%CI 25.6至43.5])(18.2个月[95%CI 17.3至19.2];风险比0.53[95%CI 0.44-0.63];p<0.001)。校正预后因素后,OS差异仍然存在(校正后风险比1.58[95%CI 1.32-1.90];p<0.001)。结论:这项基于全国登记系统的研究表明,12%的切除的PDAC与PCN相关。与不伴有PCN的PDAC相比,PCN-PDAC患者的OS更好。